Glomerulonephritis. Glomerulonephritis
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group receive 10 mg Empagliflozin tablets (Gloripa brand, Abidi Pharmaceutical Company, Tehran, 8 km of Shahid Lashkari Highway, Abidi Boulevard, N
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age more than 18 years old Have at least 500 mg of proteinuria in 24-hour urine and glomerulonephritis and Have a stable condition in proteinuria during the last three months Have eGFR=30 mL/min Written consent to participate in the study Do not use empagliflozin before entering the study Absence of recurrent urinary tract infections Pregnant and lactating patients are not entered in the study
Exclusion criteria
Exclusion criteria: Hypersensitivity reaction to empagliflozin Unwillingness to continue cooperating in the study or not referring for further follow-up Drug or dosage of drugs modification that may affect proteinuria (such as ACEI, ARB, aldosterone blockers, CNI, Mycophenolate, non-dihydropyridine calcium channel blockers) Decreased patient's FBS less than 70 mg / dL during the study Recurrent urinary tract infections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proteinuria. Timepoint: Before starting the study and then three months later. Method of measurement: Measurement of protein in the patient's 24-hour urine. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improve kidney function. Timepoint: At the start and at the end of study. Method of measurement: Measurement of serum creatinine and calculation of eGFR. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShahram Taheri
Esfahan University of Medical Sciences
Outcome results
None listed